Barclays’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-98,327
| Closed | -$3.96M | – | 5348 |
|
|
2026
Q1 | $3.96M | Sell |
98,327
-89,385
| -48% | -$1.93M | ﹤0.01% | 1965 |
|
|
2025
Q4 | $4.72M | Sell |
187,712
-81,815
| -30% | -$1.92M | ﹤0.01% | 2264 |
|
|
2025
Q3 | $6.1M | Sell |
269,527
-4,385
| -2% | -$102K | ﹤0.01% | 2044 |
|
|
2025
Q2 | $4.74M | Buy |
273,912
+82,675
| +43% | +$1.53M | ﹤0.01% | 2179 |
|
|
2025
Q1 | $4.18M | Buy |
191,237
+31,672
| +20% | +$875K | ﹤0.01% | 2052 |
|
|
2024
Q4 | $5.09M | Sell |
159,565
-96,332
| -38% | -$2.9M | ﹤0.01% | 2153 |
|
|
2024
Q3 | $7.38M | Buy |
255,897
+39,019
| +18% | +$1.45M | ﹤0.01% | 1716 |
|
|
2024
Q2 | $8.32M | Buy |
216,878
+191,086
| +741% | +$8.65M | ﹤0.01% | 1271 |
|
|
2024
Q1 | $1.52M | Sell |
25,792
-170,599
| -87% | -$10.9M | ﹤0.01% | 2794 |
|
|
2023
Q4 | $11.8M | Sell |
196,391
-146,498
| -43% | -$7.43M | ﹤0.01% | 1392 |
|
|
2023
Q3 | $13M | Buy |
342,889
+30,659
| +10% | +$1.35M | 0.01% | 889 |
|
|
2023
Q2 | $28.4M | Buy |
312,230
+70,049
| +29% | +$6.04M | 0.02% | 612 |
|
|
2023
Q1 | $16M | Buy |
242,181
+14,834
| +7% | +$856K | 0.01% | 952 |
|
|
2022
Q4 | $11.8M | Buy |
227,347
+94,198
| +71% | +$5M | 0.01% | 1127 |
|
|
2022
Q3 | $9.1M | Buy |
133,149
+109,713
| +468% | +$6.49M | 0.01% | 890 |
|
|
2022
Q2 | $1.06M | Sell |
23,436
-29,168
| -55% | -$1.33M | ﹤0.01% | 2302 |
|
|
2022
Q1 | $2.67M | Sell |
52,604
-92,644
| -64% | -$4.09M | ﹤0.01% | 1651 |
|
|
2021
Q4 | $6.87M | Buy |
145,248
+112,555
| +344% | +$4.43M | ﹤0.01% | 1494 |
|
|
2021
Q3 | $1.08M | Sell |
32,693
-4,426
| -12% | -$249K | ﹤0.01% | 2747 |
|
|
2021
Q2 | $2.35M | Sell |
37,119
-54,915
| -60% | -$2.83M | ﹤0.01% | 2087 |
|
|
2021
Q1 | $3.95M | Buy |
92,034
+3,404
| +4% | +$161K | ﹤0.01% | 1720 |
|
|
2020
Q4 | $5.07M | Sell |
88,630
-72,188
| -45% | -$3.05M | ﹤0.01% | 1515 |
|
|
2020
Q3 | $4.85M | Buy |
160,818
+97,314
| +153% | +$2.91M | ﹤0.01% | 1417 |
|
|
2020
Q2 | $2.07M | Sell |
63,504
-126,534
| -67% | -$4.06M | ﹤0.01% | 2085 |
|
|
2020
Q1 | $5.09M | Sell |
190,038
-970,396
| -84% | -$34.5M | ﹤0.01% | 1455 |
|
|
2019
Q4 | $35.5M | Buy |
1,160,434
+1,113,185
| +2,356% | +$30.8M | 0.02% | 655 |
|
|
2019
Q3 | $1.14M | Sell |
47,249
-71,889
| -60% | -$1.98M | ﹤0.01% | 3534 |
|
|
2019
Q2 | $3.02M | Buy |
119,138
+39,983
| +51% | +$813K | ﹤0.01% | 2429 |
|
|
2019
Q1 | $1.54M | Buy |
79,155
+77,574
| +4,907% | +$1.22M | ﹤0.01% | 2886 |
|
|
2018
Q4 | $21K | Sell |
1,581
-12,473
| -89% | -$191K | ﹤0.01% | 5867 |
|
|
2018
Q3 | $251K | Buy |
14,054
+11,406
| +431% | +$211K | ﹤0.01% | 4826 |
|
|
2018
Q2 | $58K | Buy |
2,648
+281
| +12% | +$6.46K | ﹤0.01% | 5565 |
|
|
2018
Q1 | $53K | Buy |
2,367
+650
| +38% | +$12.8K | ﹤0.01% | 5863 |
|
|
2017
Q4 | $37K | Buy |
+1,717
| New | +$25.3K | ﹤0.01% | 5926 |
|
Other funds holding APLS
Barclays's APLS Position: Q2 2026 in Review
Barclays sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 98,327 shares — an estimated $3.96M sold.
Barclays first reported a position in APLS in Q4 2017 and held it in 34 quarters. The position peaked at $35.5M in Q4 2019. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- Barclays reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Barclays sold 98,327 Apellis Pharmaceuticals shares in Q2 2026, an estimated $3.96M.
- Barclays first reported a position in Apellis Pharmaceuticals in Q4 2017 and held it in 34 quarters.
- Barclays's Apellis Pharmaceuticals position peaked at $35.5M in Q4 2019.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.